kabutan

Fuso Pharma, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 83%, Oct-Dec Ordinary Profit Increases by 64%

Mon Feb 10, 2025 1:40 pm JST Earnings

4538 Fuso Pharmaceutical Industries,Ltd. 【J-GAAP】

Earnings Report

Fuso Pharmaceutical Industries,Ltd. <4538> [TSE Prime] announced its financial results in the afternoon session on February 10th (13:40). The ordinary profit (non-consolidated) for the cumulative third quarter of the fiscal year ending March 2025 (April to December) expanded 3.34 billion yen, an increase 82.7% compared to the same period last year. The progress rate toward the full-year plan of 3.7 billion yen was 90.3%, it was below the five-year average of 99.2%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the ordinary profit for the January to March period (4Q) is expected to surge 9.2 times that of the same period last year, reaching 0.35 billion yen.

In the most recent three-month period, from October to December (3Q), the ordinary profit increased 63.9% from the same period last year, reaching 1.19 billion yen. The operating profit margin improved from 4.8% in the same period last year to 7.1%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2022 39,219 1,965 2,060 1,493 170.3 93.0 Feb 10, 2023 J-GAAP
Apr - Dec, 2023 42,830 1,843 1,829 1,227 141.9 97.9 Feb 13, 2024 J-GAAP
Apr - Dec, 2024 46,659 3,633 3,341 2,402 281.3 90.3 Feb 10, 2025 J-GAAP
YoY +8.9% +97.1% +82.7% +95.8% +98.2%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 27,983 865 770 660 76.7 35 May 10, 2024 J-GAAP
Oct - Mar, 2024 Guidance 30,261 1,566 1,557 1,065 124.7 42 Nov 11, 2024 J-GAAP
YoY +8.1% +81.0% +102.2% +61.4% +62.6%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 51,015 2,206 2,215 1,605 183.1 70 May 10, 2023 J-GAAP
Mar, 2024 55,407 1,964 1,868 1,377 160.0 70 May 10, 2024 J-GAAP
Mar, 2025 Guidance 60,000 4,000 3,700 2,600 304.4 82 Nov 11, 2024 J-GAAP
YoY +8.3% +103.7% +98.1% +88.8% +90.3%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2023 15,406 744 731 510 59.0 4.8 Feb 13, 2024 J-GAAP
Jan - Mar, 2024 12,577 121 39 150 17.4 1.0 May 10, 2024 J-GAAP
Apr - Jun, 2024 14,622 1,150 909 632 74.1 7.9 Aug 8, 2024 J-GAAP
Jul - Sep, 2024 15,117 1,284 1,234 903 105.7 8.5 Nov 11, 2024 J-GAAP
Oct - Dec, 2024 16,920 1,199 1,198 867 101.5 7.1 Feb 10, 2025 J-GAAP
YoY +9.8% +61.2% +63.9% +70.0% +72.1%

Related Articles